StemCells, Inc. (NASDAQ:STEM)

CAPS Rating: 2 out of 5

A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.

Recs

0
Player Avatar KimLanners (< 20) Submitted: 7/7/2011 10:42:06 AM : Outperform Start Price: $4.87 STEM Score: -82.82

stemcells

Featured Broker Partners


Advertisement